Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for alzheimer’s disease diagnosis in a memory clinic cohort

HIGHLIGHTS

• who: Christophe Hirtz from the the Washington University or Shimadzu (IPMS-Shim) [14, ]A study relying on Simoa reported decreased plasma Au03b2, and Au03b2, concentrations and reduced Au03b242/, in AD patients [16]. Such biomarkers could even discriminate mild cognitive impairment (MCI) from control individuals [16] and were relevant predictive tools of positive amyloid-PET status [17]. MS-based studies found similar results indicating that Au03b242/, was inversely proportional to brain Au03b2 burden [15]. However, data are still incomplete in clinical practice and concerning the diagnostic and prognostic accuracy of Au03b2 plasma biomarkers to discriminate AD from MCI . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.